FDA Panel Votes To Restrict GSK's Avandia

Law360, New York (July 14, 2010, 4:33 PM EDT) -- A divided U.S. Food and Drug Administration advisory committee voted Wednesday to keep GlaxoSmithKline PLC's troubled diabetes drug Avandia on the market, although nearly one-third of the panelists recommended that the pill be banned outright.

Following two days of presentations from drugmakers, clinicians and FDA staff members, a joint panel of the agency's Endocrinologic and Metabolic Drugs advisory committee and Drug Safety and Risk Management advisory committee determined that rosiglitazone — the active ingredient in Avandia — presents an elevated risk of heart complications in diabetes...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.